Procter & Gamble’s Sales Rose 1.5%. Profitability Fell.

The main change was a widening gap between sales and profitability. Derived Q4 FY2026 revenue was $21.20B, up 1.5% from $20.89B in Q4 FY2025. That was a modest improvement rather than a growth acceleration: Q1 and Q2 revenue had been $22.39B and $22.21B, respectively, before declining to $21.23B in Q3 and $21.20B in Q4. The quarter therefore ended with positive year-over-year growth but little sequential momentum.

Profit did not follow revenue higher. Q4 EPS fell to $1.26 from $1.48 a year earlier, a decline of 14.9%. The supplied operating-margin field is designated as pre-tax margin for this company; on that basis, Q4 profitability declined to 18.6% from 20.8%, a contraction of 220 basis points. Gross margin was not disclosed in the supplied data, so the evidence does not show whether the deterioration came from product costs, operating expenses, non-operating items or some combination.

Cash generation was more resilient. Derived quarterly free cash flow was $4.11B, compared with $3.99B a year earlier, an increase of 3.0%. Under the supplied company classification, free cash flow is not treated as a primary valuation metric, so we use it only as supporting evidence rather than the core measure of economic performance. The more relevant conclusion is that weaker accounting profitability did not coincide with an equivalent decline in reported cash generation.

The full-year picture was less negative than the fourth quarter alone. FY2026 revenue rose 3.3% to $87.03B from $84.28B, while EPS increased 1.7% to $6.62 from $6.51. Pre-tax margin nevertheless declined to 22.7% from 24.3%, a 160-basis-point contraction. Operating cash flow was $19.56B and capital expenditure was $4.41B, as reported in the Procter & Gamble FY2026 Form 10-K.

The quarter does not challenge the demand-resilience argument, but it does weaken the earnings-quality side of the case. Revenue remained positive year over year, and annual revenue reached a new high in the supplied ten-year series. Yet a 1.5% quarterly sales gain accompanied by a 14.9% EPS decline shows that small changes below the revenue line can outweigh modest top-line growth.

That distinction matters at the current valuation. Procter & Gamble trades at 21.6x trailing EPS of $6.62. A multiple above 20x can be sustained when earnings are dependable and margins are stable, but the latest quarter offered only half of that combination. Sales held up; profitability did not. Without disclosed volume, pricing and cost details, it is not possible to determine whether the margin decline was temporary or reflects a more persistent mismatch between pricing and expenses.

The annual record remains stronger than the fourth-quarter result. Revenue increased from $65.06B in FY2017 to $87.03B in FY2026, while EPS recovered from unusually low levels in FY2019 and reached $6.62 in FY2026. More recently, however, EPS increased by just $0.11 year over year despite $2.75B of additional revenue. That incremental conversion is the key issue to monitor in FY2027.

The balance sheet provides a partial offset. Cash was $9.94B and debt was $22.84B at fiscal year-end, resulting in supplied net debt of $12.90B. That was down from $15.44B in FY2025 and was the lowest year-end level since FY2021. Leverage therefore does not appear to be the immediate thesis risk. The more relevant question is whether the company can convert low-single-digit revenue growth into comparable or better EPS growth.

Because no press release was supplied, there is no company guidance midpoint against which to judge the quarter. The report card therefore uses Q4 FY2025 as its reference, as required. It also means the analysis cannot attribute changes to management’s stated outlook, strategic actions or category trends. The evidence supports a cautious reading rather than a definitive conclusion about the source of the margin pressure.

There was no prior SageNoodle valuation to update, so this report establishes an initial baseline. We use a trailing P/E approach because the supplied classification directs the analysis toward revenue, pre-tax income, EPS, book value and capital rather than gross margin, free-cash-flow yield or ROIC. EV/EBITDA was not disclosed and is shown as not meaningful in the snapshot through a zero placeholder; the same treatment applies to free-cash-flow yield and ROIC.

The base case applies a 22.0x multiple to FY2026 EPS of $6.62, producing fair value of $145.64 per share. The multiple is an explicit valuation assumption, not company guidance or a consensus estimate. It represents a modest premium to the current 21.6x trailing multiple and assumes the Q4 margin decline does not become a sustained deterioration. At the current price of $142.97, implied upside is only 1.9%, which meets SageNoodle’s Fairly Valued definition.

The bear case applies 18.0x to the same $6.62 EPS base for fair value of $119.16. It assumes the weaker Q4 margin is an early sign that low-single-digit sales growth will not translate into earnings growth. The bull case applies 25.0x, producing $165.50, and assumes the company restores margin stability while preserving its revenue base and balance-sheet improvement.

These scenarios intentionally do not forecast undisclosed FY2027 EPS. Using the reported trailing figure keeps the valuation grounded in the supplied financials and makes the multiple assumptions transparent. The resulting range is wide enough to capture the principal tension: this is a durable revenue base, but the current price leaves limited room for additional margin erosion.

The bearish interpretation would be wrong if the Q4 EPS and pre-tax margin declines were caused by temporary or non-recurring items. The supplied quarterly table does not provide an expense bridge, and no earnings release was available. A subsequent filing showing normalized margins recovering without unusually aggressive cost reductions would support a higher multiple.

The base valuation would also be too conservative if FY2027 delivers stronger earnings growth than FY2026 without requiring substantially faster revenue growth. The clearest evidence would be pre-tax margin moving back toward FY2025’s 24.3% while revenue remains positive. That combination would suggest the latest quarter was a trough rather than a new operating baseline.

Conversely, the thesis would weaken if revenue growth slows further while pre-tax margin remains below prior-year levels. At 21.6x trailing earnings, the shares are not priced like a turnaround. Repeated quarters in which EPS trails revenue would challenge the assumption that Procter & Gamble deserves a premium multiple for consistency.

Balance-sheet deterioration is a secondary risk. Net debt improved by $2.54B during FY2026, but that progress could reverse if cash generation weakens or capital demands rise. The available data do not indicate an immediate leverage problem, yet the valuation depends partly on the company retaining financial flexibility while it addresses the margin decline.

The final risk is analytical visibility. With no supplied press release, guidance or segment disclosure, this update cannot distinguish category weakness from cost pressure, mix or one-time effects. The next reported quarter must provide evidence on margin direction. Until then, $145.64 is a reasonable anchor rather than a high-conviction claim of undervaluation.